The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation
- PMID: 21103971
- DOI: 10.1007/978-3-642-14541-4_5
The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation
Abstract
Bile formation is an important function of the liver. Bile salts are a major constituent of bile and are secreted by hepatocytes into bile and delivered into the small intestine, where they assist in fat digestion. In the small intestine, bile salts are almost quantitatively reclaimed and transported back via the portal circulation to the liver. In the liver, hepatocytes take up bile salts and secrete them again into bile for ongoing enterohepatic circulation. Uptake of bile salts into hepatocytes occurs largely in a sodium-dependent manner by the sodium taurocholate cotransporting polypeptide NTCP. The transport properties of NTCP have been extensively characterized. It is an electrogenic member of the solute carrier family of transporters (SLC10A1) and transports predominantly bile salts and sulfated compounds, but is also able to mediate transport of additional substrates, such as thyroid hormones, drugs and toxins. It is highly regulated under physiologic and pathophysiologic conditions. Regulation of NTCP copes with changes of bile salt load to hepatocytes and prevents entry of cytotoxic bile salts during liver disease. Canalicular export of bile salts is mediated by the ATP-binding cassette transporter bile salt export pump BSEP (ABCB11). BSEP constitutes the rate limiting step of hepatocellular bile salt transport and drives enterohepatic circulation of bile salts. It is extensively regulated to keep intracellular bile salt levels low under normal and pathophysiologic situations. Mutations in the BSEP gene lead to severe progressive familial intrahepatic cholestasis. The substrates of BSEP are practically restricted to bile salts and their metabolites. It is, however, subject to inhibition by endogenous metabolites or by drugs. A sustained inhibition will lead to acquired cholestasis, which can end in liver injury.
Similar articles
-
Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs.Drug Metab Dispos. 2006 Sep;34(9):1575-81. doi: 10.1124/dmd.105.008748. Epub 2006 Jun 7. Drug Metab Dispos. 2006. PMID: 16760228
-
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis.Hepatology. 2005 May;41(5):1160-72. doi: 10.1002/hep.20682. Hepatology. 2005. PMID: 15841457
-
The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity.Toxicol Mech Methods. 2015;25(5):382-7. doi: 10.3109/15376516.2015.1033074. Epub 2015 Apr 17. Toxicol Mech Methods. 2015. PMID: 25886055
-
The canalicular bile salt export pump BSEP (ABCB11) as a potential therapeutic target.Curr Drug Targets. 2011 May;12(5):661-70. doi: 10.2174/138945011795378496. Curr Drug Targets. 2011. PMID: 21039337 Review.
-
Hepatic transport of bile salts.Semin Liver Dis. 2000;20(3):273-92. doi: 10.1055/s-2000-9426. Semin Liver Dis. 2000. PMID: 11076396 Review.
Cited by
-
Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression.J Biol Chem. 2015 Feb 27;290(9):5673-84. doi: 10.1074/jbc.M114.602540. Epub 2014 Dec 30. J Biol Chem. 2015. PMID: 25550158 Free PMC article.
-
The mechanism of enterohepatic circulation in the formation of gallstone disease.J Membr Biol. 2014 Nov;247(11):1067-82. doi: 10.1007/s00232-014-9715-3. Epub 2014 Aug 9. J Membr Biol. 2014. PMID: 25107305 Free PMC article. Review.
-
Impact on Bile Acid Concentrations by Alveolar Echinococcosis and Treatment with Albendazole in Mice.Metabolites. 2021 Jul 6;11(7):442. doi: 10.3390/metabo11070442. Metabolites. 2021. PMID: 34357336 Free PMC article.
-
Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNα-2a as Treatment for Chronic Hepatitis Delta.Liver Int. 2025 Feb;45(2):e70008. doi: 10.1111/liv.70008. Liver Int. 2025. PMID: 39853842 Free PMC article. Clinical Trial.
-
Impact of hepatitis B virus infection on hepatic metabolic signaling pathway.World J Gastroenterol. 2016 Sep 28;22(36):8161-7. doi: 10.3748/wjg.v22.i36.8161. World J Gastroenterol. 2016. PMID: 27688657 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources